Pharmacology of Parkinson's Disease

Overview

• Parkinson's Disease: A neurodegenerative disease affecting dopaminergic neurons in the brain's substantia nigra.
• Importance: Dopaminergic neurons secrete dopamine, crucial for controlled movement.

Pathophysiology

• Normal State:

  • Dopaminergic neurons release dopamine, influencing GABAergic neurons in the caudate striatum.
  • GABAergic neurons receive signals from dopamine receptors, which can stimulate or inhibit them.
  • Monoamine oxidase enzyme breaks down dopamine after use, aiding recycling.

• Parkinson's Disease State:

  • Degeneration of dopaminergic neurons leads to decreased dopamine production.
  • Results in decreased dopamine in the synaptic cleft.
  • These neurons are protected by the blood-brain barrier.

Treatment Strategies

• Main goal: Increase dopamine levels.

Levodopa

• Precursor to dopamine that can cross the blood-brain barrier, unlike dopamine.

• Peripheral Issues:

  • In the periphery, levodopa can be broken down into dopamine by dopamine carboxylase, which is ineffective if dopamine is produced outside the brain.
  • Solution: Use decarboxylase inhibitors (e.g., Carbidopa) to prevent peripheral breakdown.

• Alternative Pathways:

  • Levodopa can also be broken down into 3-O-Methyldopa (3-OMD) by COMT.
  • Solution: Use COMT inhibitors to prevent this breakdown.

• Mechanism:

  • Levodopa enters dopaminergic neurons and gets converted into dopamine, alleviating symptoms.

Other Drugs

• Dopamine Agonists: Bind and activate dopamine receptors, mimicking dopamine.
• Monoamine Oxidase Inhibitors: Prevent dopamine breakdown by inhibiting monoamine oxidase, prolonging dopamine's availability.

Summary

• First-line Treatment: Levodopa (administered with peripheral dopamine carboxylase inhibitors).
• Additional Options: Dopamine agonists, Monoamine oxidase inhibitors.

This lecture provided a brief overview of the pharmacology related to Parkinson's Disease treatment.